Charles River Laboratories
$ 267.49
0.75%
07 Aug - close price
- Market Cap 12,769,670,000 USD
- Current Price $ 267.49
- High / Low $ 267.59 / 260.82
- Stock P/E N/A
- Book Value 59.50
- EPS -4.84
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE -0.08 %
- 52 Week High 268.00
- 52 Week Low 144.26
About
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Analyst Target Price
$267.71
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-07 | 2026-02-18 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-19 | 2024-11-06 | 2024-08-07 | 2024-05-09 | 2024-02-14 | 2023-11-08 |
| Reported EPS | 3.02 | 2.06 | 2.39 | 2.43 | 3.12 | 2.34 | 2.66 | 2.59 | 2.8 | 2.27 | 2.46 | 2.72 |
| Estimated EPS | 2.72 | 1.95 | 2.33 | 2.32 | 2.55 | 2.07 | 2.53 | 2.42 | 2.39 | 2.06 | 2.4 | 2.37 |
| Surprise | 0.3 | 0.11 | 0.06 | 0.11 | 0.57 | 0.27 | 0.13 | 0.17 | 0.41 | 0.21 | 0.06 | 0.35 |
| Surprise Percentage | 11.0294% | 5.641% | 2.5751% | 4.7414% | 22.3529% | 13.0435% | 5.1383% | 7.0248% | 17.1548% | 10.1942% | 2.5% | 14.7679% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRL
2026-08-08 01:10:53
Broadstone Net Lease (BNL) reported strong Q2 2026 results, highlighted by a significant $303 million build-to-suit agreement in Colorado for a Fortune 20 tenant, which will become its largest source of annualized base rent upon completion in 2027. The company raised its full-year 2026 investment guidance to $600-$800 million and increased its AFFO per share midpoint to $1.56, reflecting confidence in its portfolio and investment pipeline. BNL is also actively pursuing redevelopments and exploring the potential of its Project Triboro site for hyperscale data centers, expecting to decide on its highest and best use by year-end.
2026-08-07 16:37:27
Royal Bank of Canada reduced its stake in Charles River Laboratories International (NYSE:CRL) by 18.9% in the first quarter, selling 23,345 shares but still holding 100,311 shares valued at $17.3 million. Despite a year-over-year revenue decline, Charles River Laboratories exceeded Q2 earnings and revenue expectations and raised its fiscal 2026 guidance, driven by improving biotech demand. Analysts currently have a "Moderate Buy" consensus rating for CRL with an average price target of $244.19, though underlying risks like continued weakness in the Resources Management Services segment remain.
2026-08-07 07:07:33
Charles River Laboratories International (CRL) reported mixed Q2 2026 results, cutting its GAAP EPS guidance due to divestiture losses but raising its full-year adjusted earnings outlook. This was driven by stronger-than-expected performance in its Discovery and Safety Assessment (DSA) segment, supported by portfolio changes and lower non-human primate sourcing costs. Investors are now evaluating whether this DSA-driven momentum and cost reductions can lead to more sustainable earnings, despite ongoing risks related to divestitures and GAAP losses.
2026-08-07 05:37:35
Charles River Laboratories, a company specializing in animal research models and drug development services, is experiencing an improving demand environment, leading to a stronger near-term outlook. Despite not having an economic moat, the company's business strategy, which serves nearly all top biopharma players, is benefiting from these market conditions. This positive development is highlighted in a recent stock analyst note from Morningstar.
2026-08-07 03:07:36
An insider at Charles River Laboratories (NYSE: CRL) plans to sell 4,300 shares from Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) granted in 2022, along with 2,345 shares from a stock option exercise. The anticipated sale date is August 6, 2026, with transactions handled by UBS Financial Services Inc. and listed on the NYSE. This Rule 144 filing indicates a neutral impact and sentiment, detailing the equity awards and their planned disposition.
2026-08-07 03:07:27
Deutsche Bank has increased its price target for Charles River Laboratories International (CRL) to $300 from $260, while reiterating a Buy rating on the stock. The article indicates that Charles River Laboratories International currently holds an average rating of "overweight" among analysts. The full details are available to premium subscribers.
